AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1457788 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese DPDP (5 mumol/kg, 10 mumol/ml concentration)
Number of subjects: 20
Study 6373481 — intervention group
Group type: EXPERIMENTAL
Intervention: Optocillin (mezlocillin and oxacillin) 6 gs after clamping the umbilical cord and after 8 and 16 hours
Number of subjects: 100
Study 31282364 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 0
Study 31282364 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous liraglutide
Number of subjects: 0
Study 31282364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29886442 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided method (UGM)
Number of subjects: 114
Study 29886442 — intervention group
Group type: COMPARATOR
Intervention: Landmark method (LM)
Number of subjects: 114
Study 25900558 — intervention group
Group type: EXPERIMENTAL
Intervention: RADPAD® drape
Number of subjects: 50
Study 25900558 — intervention group
Group type: COMPARATOR
Intervention: No RADPAD® drape
Number of subjects: 50
Study 23928104 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS at 110% of motor threshold (MT)
Number of subjects: 24
Study 23928104 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS at 110% of motor threshold (MT)
Number of subjects: 24
Study 23928104 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 24
Study 23002259 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg, 0.5% hyperbaric bupivacaine with the Whitacre needle oriented laterally
Number of subjects: 0
Study 23002259 — intervention group
Group type: COMPARATOR
Intervention: 10 mg, 0.5% hyperbaric bupivacaine with the Whitacre needle oriented cephalad
Number of subjects: 0
Study 20418792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartilage palisade tympanoplasty (CPT)
Number of subjects: 123
Study 20418792 — intervention group
Group type: COMPARATOR
Intervention: Tympanoplasty with temporalis muscle fascia (FT)
Number of subjects: 123
Study 18752991 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-channel banana-avg montage
Number of subjects: 100
Study 18752991 — intervention group
Group type: COMPARATOR
Intervention: 16-channel double banana montage
Number of subjects: 100
Study 15676041 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral artemisinin daily for 5 days
Number of subjects: 24
Study 15676041 — intervention group
Group type: COMPARATOR
Intervention: Single oral doses of 100/100/250/250/500 mg on each of the first 5 days
Number of subjects: 24
Study 12066424 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjective-based sentences
Number of subjects: 0
Study 12066424 — intervention group
Group type: EXPERIMENTAL
Intervention: Noun-based materials
Number of subjects: 0
Study 12066424 — intervention group
Group type: COMPARATOR
Intervention: Noun-based sentences
Number of subjects: 0
Study 10359405 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg plus 400 microg daily for 6 months followed by 400 microg twice daily for 30 months
Number of subjects: 290
Study 10359405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 10359405 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 290
Study 2127335 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vancomycin administered into the ventricular system during surgery
Number of subjects: 158
Study 2127335 — intervention group
Group type: COMPARATOR
Intervention: Current antimicrobial regimen used in the centre
Number of subjects: 158
Study 6113060 — intervention group
Group type: EXPERIMENTAL
Intervention: systematic desensitization 'in vivo'
Number of subjects: 38
Study 6113060 — intervention group
Group type: EXPERIMENTAL
Intervention: systematic desensitization 'in imagination'
Number of subjects: 38
Study 6113060 — intervention group
Group type: COMPARATOR
Intervention: no treatment control
Number of subjects: 38
Study 31952627 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU+CBT4CBT
Number of subjects: 83
Study 31952627 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 83
Study 31006038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 15 mg/m2 per day, 4-weeks-on/2-weeks-off (schedule 4/2), with intra-patient dose escalation to 22.5 and subsequently 30 mg/m2 based on tolerability.
Number of subjects: 6
Study 30061768 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosil mouthwash (oral decontamination program performed three times a day for five days)
Number of subjects: 80
Study 30061768 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine 0.12% (oral decontamination program performed three times a day for five days)
Number of subjects: 80
Study 30061768 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosil mouthwash
Number of subjects: 80
Study 30061768 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine 0.12%
Number of subjects: 80
Study 30061768 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosil mouthwash and Chlorhexidine 0.12%
Number of subjects: 80
Study 27185721 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD-diclofenac
Number of subjects: 608
Study 27185721 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 608
Study 27185721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study 27185721 — intervention group
Group type: COMPARATOR
Intervention: HPβCD-diclofenac vs Placebo
Number of subjects: 608
Study 25337871 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 21115
Study 25337871 — intervention group
Group type: COMPARATOR
Intervention: Open Repair
Number of subjects: 21115
Study 25337871 — intervention group
Group type: COMPARATOR
Intervention: Comparison of EVAR to Open Repair
Number of subjects: 21115
Study 25337871 — intervention group
Group type: COMPARATOR
Intervention: Men vs Women
Number of subjects: 21115
Study 25337871 — intervention group
Group type: COMPARATOR
Intervention: NSQIP cohort vs OVER trial
Number of subjects: 21115
Study 25337871 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal trends in EVAR usage
Number of subjects: 21115
Study 25337871 — intervention group
Group type: COMPARATOR
Intervention: Change in perioperative mortality over time
Number of subjects: 21115
Study 21811769 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 87
Study 21811769 — intervention group
Group type: EXPERIMENTAL
Intervention: Monarc sling
Number of subjects: 87
Study 21811769 — intervention group
Group type: COMPARATOR
Intervention: Both groups (TVT and Monarc)
Number of subjects: 87
Study 19884037 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine manual therapy (lateral glide)
Number of subjects: 39
Study 19884037 — intervention group
Group type: COMPARATOR
Intervention: Manual contact intervention
Number of subjects: 39
Study 17335465 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 25 mg twice daily
Number of subjects: 53
Study 17335465 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 10, 25, and 50 mg at night-time
Number of subjects: 53
Study 17335465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Lamotrigine and Amitriptyline)
Number of subjects: 53
Study 17335465 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 53
Study 17335465 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 53
Study 15765335 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright-light measurement
Number of subjects: 136
Study 15765335 — intervention group
Group type: EXPERIMENTAL
Intervention: Room-light measurement
Number of subjects: 136
Study 15765335 — intervention group
Group type: COMPARATOR
Intervention: Gestalt judgment
Number of subjects: 136
Study 11877357 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 728
Study 11877357 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based regimen
Number of subjects: 728
Study 10344555 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (Mitoxantrone: 45 mg/m2, Cyclophosphamide: 120 mg/kg, Melphalan: 140 mg/m2)
Number of subjects: 61
Study 10344555 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (conventional chemotherapy)
Number of subjects: 61
Study 10344555 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy
Number of subjects: 61
Study 10344555 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 61
Study 8944393 — intervention group
Group type: EXPERIMENTAL
Intervention: meta-chlorophenylpiperazine (mCPP)
Number of subjects: 40
Study 8944393 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 1758944 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 110
Study 1758944 — intervention group
Group type: COMPARATOR
Intervention: Support therapy
Number of subjects: 110
Study 7057858 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing education packages covering clinical problems
Number of subjects: 16
Study 7057858 — intervention group
Group type: COMPARATOR
Intervention: Control group (no continuing education packages)
Number of subjects: 16
Study 31493677 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Number of subjects: 145
Study 31493677 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 145
Study 29758255 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional method (T)
Number of subjects: 104
Study 29758255 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified method (S)
Number of subjects: 104
Study 29758255 — intervention group
Group type: COMPARATOR
Intervention: Both methods (T and S)
Number of subjects: 104
Study 26577683 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily budesonide 2mg foam
Number of subjects: 165
Study 24480430 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSC group received subcutaneous G-CSF injections (15 µg/kg/day) for 5 consecutive days, followed by stereotaxic implantation of 3-8 × 10(6) CD34(+) immunosorted PBSCs.
Number of subjects: 30
Study 24480430 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 30
Study 24480430 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSC group (details as above).
Number of subjects: 30
Study 23285483 — intervention group
Group type: EXPERIMENTAL
Intervention: Far infrared emitting plaster
Number of subjects: 60
Study 23285483 — intervention group
Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 60
Study 20807120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-intensity exercise (IHE)
Number of subjects: 8
Study 20807120 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity exercise (MOD)
Number of subjects: 8
Study 17598500 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive, population-based, organised cervical cancer prevention programmes integrating cervical screening with new technologies and vaccines
Number of subjects: 0
Study 15768872 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingxin capsule (QXC)
Number of subjects: 98
Study 15768872 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 98
Study 15768872 — intervention group
Group type: EXPERIMENTAL
Intervention: QXC plus captopril
Number of subjects: 98
Study 15768872 — intervention group
Group type: EXPERIMENTAL
Intervention: QXC
Number of subjects: 98
Study 12191719 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (PY) at 212+/‐25 microg/kg body weight
Number of subjects: 8
Study 12191719 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of beta‐glucuronidase to urine samples
Number of subjects: 8
Study 11256036 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms levothyroxine + 100 micrograms iodide
Number of subjects: 44
Study 11256036 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 micrograms levothyroxine + 150 micrograms iodide
Number of subjects: 44
Study 9505778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 25 mg
Number of subjects: 210
Study 9505778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 210
Study 9505778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 25 mg + Ranitidine 75 mg
Number of subjects: 210
Study 9505778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 7797216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting posture (Group I)
Number of subjects: 0
Study 7797216 — intervention group
Group type: COMPARATOR
Intervention: Lying down posture (Group II)
Number of subjects: 0
Study 3134082 — intervention group
Group type: EXPERIMENTAL
Intervention: Paranormal healing by laying on of hands
Number of subjects: 115
Study 3134082 — intervention group
Group type: EXPERIMENTAL
Intervention: Paranormal healing at a distance
Number of subjects: 115
Study 3134082 — intervention group
Group type: COMPARATOR
Intervention: No paranormal healing (control)
Number of subjects: 115
Study 19585923 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirituality counseling
Number of subjects: 31
Study 19585923 — intervention group
Group type: COMPARATOR
Intervention: Dietitian-only arm (Control)
Number of subjects: 31
Study 343743 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 250 mg twice a day
Number of subjects: 132
Study 343743 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg taken at bedtime
Number of subjects: 132
Study 343743 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg four times a day
Number of subjects: 132
Study 343743 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (single daily dose)
Number of subjects: 132
Study 343743 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 132
Study 30702366 — intervention group
Group type: EXPERIMENTAL
Intervention: Resisted sled sprinting (RSS) at a sled load of 30% body mass for a total program running distance of 800 m
Number of subjects: 13
Study 30702366 — intervention group
Group type: COMPARATOR
Intervention: Unresisted sprinting (URS) for the same distance of 800 m
Number of subjects: 13
Study 30073267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implants (CIs)
Number of subjects: 46
Study 30073267 — intervention group
Group type: COMPARATOR
Intervention: Normal Hearing (NH)
Number of subjects: 46
Study 30073267 — intervention group
Group type: COMPARATOR
Intervention: Auditory degradation
Number of subjects: 46
Study 27614164 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative whole breast radiotherapy (RT)
Number of subjects: 1187
Study 27614164 — intervention group
Group type: COMPARATOR
Intervention: No local treatment (Control)
Number of subjects: 1187
Study 23873579 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting stent (Yukon Choice)
Number of subjects: 240
Study 23873579 — intervention group
Group type: COMPARATOR
Intervention: Polymer-based paclitaxel-eluting stent (Taxus Liberté)
Number of subjects: 240
Study 22420471 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of intratumoral CD8+ tumor infiltrating lymphocytes
Number of subjects: 3403
Study 19473823 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week moderate-intensity aerobic training
Number of subjects: 24
Study 19473823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 24
Study 17356963 — intervention group
Group type: EXPERIMENTAL
Intervention: EBM educational intervention
Number of subjects: 30
Study 17356963 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication databases
Number of subjects: 30
Study 17356963 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilization of pre-appraised resources
Number of subjects: 30
Study 15687448 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-containing combination therapy
Number of subjects: 489
Study 12351435 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (600 mg/day) for 3 months
Number of subjects: 27
Study 10072479 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg thioctic acid (TA)
Number of subjects: 0
Study 10072479 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg thioctic acid (TA)
Number of subjects: 0
Study 10072479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled plasma analysis
Number of subjects: 0
Study 7552589 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate intake of 8 g/kg/day (5.5 mg/kg/minute)
Number of subjects: 20
Study 7552589 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate intake of 12 g/kg/day (8.3 mg/kg/minute)
Number of subjects: 20
Study 7552589 — intervention group
Group type: EXPERIMENTAL
Intervention: Both carbohydrate intakes
Number of subjects: 20
Study 2323402 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the family planning‐based outreach program
Number of subjects: 536
Study 2323402 — intervention group
Group type: COMPARATOR
Intervention: No participation in the family planning‐based outreach program (Control)
Number of subjects: 536
Study 6245145 — intervention group
Group type: EXPERIMENTAL
Intervention: mecillinam
Number of subjects: 49
Study 6245145 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim‐sulfamethoxazole
Number of subjects: 49
Study 6245145 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study 31464626 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) integrated treatment program including tripterygium glycosides (TGs), tanshinone IIa sodium sulfonate injection, and Chinese herbs based on syndrome differentiation
Number of subjects: 500
Study 31464626 — intervention group
Group type: COMPARATOR
Intervention: Benazepril hydrochloride tablets, low molecular weight heparin calcium injection, dipyridamole tablets, and a Chinese medicine placebo
Number of subjects: 500
Study 31464626 — intervention group
Group type: COMPARATOR
Intervention: Benazepril hydrochloride tablets, low molecular weight heparin calcium injection, dipyridamole tablets, a Chinese medicine placebo, and prednisone
Number of subjects: 500
Study 28044436 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancement program (8 weeks, including education, skills training, phone counseling, and self-management records)
Number of subjects: 47
Study 28044436 — intervention group
Group type: COMPARATOR
Intervention: Control group (pressure ulcer prevention information booklet)
Number of subjects: 47
Study 24976525 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS + DEB
Number of subjects: 85
Study 24976525 — intervention group
Group type: COMPARATOR
Intervention: BMS
Number of subjects: 85
Study 25244414 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic therapy (Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus rhamnosus, and Streptococcus thermophilus) for 4 weeks
Number of subjects: 53
Study 25244414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 21523344 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU per week)
Number of subjects: 0
Study 21523344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19652619 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week group exercise program
Number of subjects: 40
Study 17763226 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pelvic floor muscle training (PFMT) including a 1‐h individual lesson, three 1‐h group lessons, and a home training programme.
Number of subjects: 58
Study 17763226 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 58
Study 17763226 — intervention group
Group type: COMPARATOR
Intervention: Both groups received verbal instructions regarding PFMT postoperatively.
Number of subjects: 58
Study 15167471 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray-colored MTA
Number of subjects: 40
Study 15167471 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-white-colored MTA
Number of subjects: 40
Study 15167471 — intervention group
Group type: COMPARATOR
Intervention: Positive control (not specified)
Number of subjects: 40
Study 15167471 — intervention group
Group type: COMPARATOR
Intervention: Negative control (not specified)
Number of subjects: 40
Study 12040670 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemo-radiation
Number of subjects: 0
Study 12040670 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus surgical salvage treatment
Number of subjects: 0
Study 12040670 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 0
Study 12568173 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott Safeset blood conserving arterial line system
Number of subjects: 99
Study 12568173 — intervention group
Group type: COMPARATOR
Intervention: Conventional indwelling arterial line system
Number of subjects: 99
Study 7553996 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC sevoflurane (S1)
Number of subjects: 38
Study 7553996 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 MAC sevoflurane (S2)
Number of subjects: 38
Study 7553996 — intervention group
Group type: COMPARATOR
Intervention: 1 MAC halothane (H1)
Number of subjects: 38
Study 7553996 — intervention group
Group type: COMPARATOR
Intervention: 2 MAC halothane (H2)
Number of subjects: 38
Study 2212088 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine (LA)
Number of subjects: 124
Study 2212088 — intervention group
Group type: EXPERIMENTAL
Intervention: Peridex (PX)
Number of subjects: 124
Study 2212088 — intervention group
Group type: COMPARATOR
Intervention: Hydroalcohol control
Number of subjects: 124
Study 738832 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation of unconscious fantasies of symbiotic gratification
Number of subjects: 0
Study 738832 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory experiments with double-blind procedures
Number of subjects: 0
Study 738832 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically based reports
Number of subjects: 0
Study 29981566 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefilled syringe
Number of subjects: 113
Study 29981566 — intervention group
Group type: COMPARATOR
Intervention: EpiPen
Number of subjects: 113
Study 29981566 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study 27150635 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus plantarum 299 and Bifidobacterium infantis Cure 21)
Number of subjects: 32